期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼对比多西紫杉醇治疗非小细胞肺癌的Meta分析 被引量：1

Meta analysis of gefitinib and docetaxel for non-small cell lung cancer( NSCLC)
下载PDF
导出
摘要 目的:系统评价吉非替尼与多西紫杉醇二者治疗非小细胞肺癌的有效性和安全性。方法:计算机检索Cochrane图书馆(建库至2013年第8期)、PubMed、Embase、CNKI、维普及万方数据库(截至2013年9月),同质研究采用RevMan 5.0软件进行合并分析。采用Cochrane Reviewer's handbook 5.1.0进行质量评价。结果:共纳入9个随机对照试验,包括2179例患者。与多西紫杉醇相比,吉非替尼能够提高总有效率[RR=1.40,95%CI(1.12,1.74)]和TOI改善率[RR=1.85,95%CI(1.49,2.31)],降低中性粒细胞减少发生率[RR=0.23,95%CI(0.11,0.49)]。结论:与多西紫杉醇相比,吉非替尼显示出更多的优势;尚需更多高质量的研究证明其有效性和安全性。 Objective： To evaluate the clinical efficacy and safety of gefitinib and docetaxel for NSCLC. Methods： The Cochrane Library （ Issue 8,2013 ）, PubMed, Embase, CNKI, VIP, and Wanfang database were searched （ up to September 2013 ）. Meta -analyses were performed by RevMan 5.0 software, and quatility assessment was carried out with Cochrane Reviewerg handbook 5.1.0. Results：9 randomized controlled trials （RCTs） involving 2179 patients were included in this meta analysis. The results of meta- analyses showed that ： compared to docetaxel, gefitinib could improve over response rate[ RR = 1.40,95% CI（1.12,1. 74） ] and TOIl RR = 1.85,95% CI（ 1.49,2.31 ） ] with lower hematology toxicity rate. Conclusion：Gefitinib shows more superiority for NSCLC compared to docetaxel. High quality RCTs and economic evaluation are needed.
作者 魏素文 戴晓倩 马丽 付晓燕
机构地区 兰州大学第一医院急诊科
出处 《现代肿瘤医学》 CAS 2014年第7期1581-1586,共6页 Journal of Modern Oncology
关键词 吉非替尼 多西紫杉醇 非小细胞肺癌 META分析 gefitinib docetaxel non - small cell lung cancer Meta analysis
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Siegel R,Naishadham D,Jemal A.Cancer statistics[J].CA Cancer J Clin,2012,62(1):10-29.
  • 2Chen WQ,Zeng HM,Zheng RS,et al.Cancer incidence and mortality in China[J].Chin J Cancer Res,2007,24(1):1-8.
  • 3Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J].N Engl J Med,2002,346(2):92-98.
  • 4Rosell R,Gatzemeier U,Betticher DC,et al.Phase Ⅲ randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer:a cooperative multinational trial [J].Ann Oncol,2002,13(10):1539-1549.
  • 5Cohen MH,Williams GA,Sridhara R,et al.United States Food and Drug Administration Drug Approval summary:Gefitinib(ZD1839;Gefitinib) tablets [J].Clin Cancer Res,2004,10(4):1212-1218.
  • 6Higgins GPT,Green S.Cochrane handbook for systematic reviews of interventions[J].Cochrane Collaboration,2011,9:3.
  • 7Lee DH,Park K,Kim JH,et al.Randomized phase Ⅲ trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy [J].Clin Cancer Res,2010,16(4):1307-1314.
  • 8Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):A randomised phase Ⅲ trial[J].Lancet,2008,372(9652):1809-1818.
  • 9Sekine I,Ichinose Y,Nishiwaki Y,et al.Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer:Results of a randomized phase Ⅲ study (V-15-32) of gefitinib versus docetaxel [J].Ann Oncol,2009,20(9):1483-1488.
  • 10Maruyama R,Nishiwaki Y,Tamura T,et al.Phase Ⅲ study,V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer [J].J Clin Oncol,2008,26(26):4244-4252.

二级参考文献47

共引文献21

同被引文献14

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics [ J ]. CA Cancer J Clin,2013,63 ( 1 ) : 11 - 30.
  • 2Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment [ J ]. Cancer, 1981,47 ( 1 ) :207 - 214.
  • 3Revel MP, Carette MF,Torrent M, et al. Diagnosis and standardized report for non - small cell lung cancer [ J ]. Diagn Interv Imaging, 2014,95 (7) :727 - 738.
  • 4Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma[ J ]. N Engl J Med,2009, 361 (10) :947.
  • 5Gridelli C, Ciardiello F, Gallo C, et al. First -line erlotinib followed by second -line cisplatin- gemcitabine chemotherapy in advanced non -small -cell lung cancer: the TORCH randomized trial [ J ]. J Clin Oncol,2012,30(24) :3002.
  • 6Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first - line treatment for European patients with advanced EGFR mutation - positive non - small - cell lung cancer ( EUR - TAC ) : a multicentre, open - label, randomised phase 3 trial [ J ]. Lancet Oneo1,2012,13 ( 3 ) :239 - 246.
  • 7National Comprehensive Cancer Network. NCCN clinical practiceguidelines in oncology for non -small cell lung cancer[ J]. Cane- er,2014,1:25.
  • 8Chee KL, Chris B, Richard J, et al. Impact of EGFR inhibitor in non - small cell lung cancer on progression - free and overall sur- vival : a meta - analysis [ J ]. J Natl Cancer Inst, 2013,105 ( 9 ) : 595 - 605.
  • 9P6rol M, Chouaid C, P6rol D, et al. Randomized, phase 11I study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second - line treatment, after cisplatin - gemcit- ahine induction chemotherapy in advanced non - small - cell lungcancer[J]. J Clin Oncol,2012,30(28) :3516 -3524.
  • 10Powr6zek T, Krawezyk P, Ramlau R, et al. EGFR gene mutations in patients with adenosquamous lung carcinoma [ J ]. Asia Pae J Clin 0neol,2014,10 (4) :340 - 345.

引证文献1

现代肿瘤医学
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部